Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography
Kidney360 · 2025-08 · 6 (8) · 1317-1327
DOI: 10.34067/kid.0000000781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, online erschienen am 21.03.2025. Verfasst von Theera Phatikraisri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Intervention Department, Central Chest Institute of Thailand, Nonthaburi, Thailand. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Thammasat University.
Abstract (Originalsprache)
Key Points Currently, there are no definitive guidelines regarding the appropriate management of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients undergoing coronary angiography (CAG). This is the first randomized controlled trial to our knowledge to evaluate the effects of continuing versus withholding SGLT2 inhibitors in patients undergoing elective CAG. No difference was noted in the rate of contrast-associated AKI between withholding or and continuing SGLT2 inhibitors during elective CAG.
Background
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly recognized as first-line treatments of type 2 diabetes mellitus, CKD, and heart failure. However, periprocedural management of SGLT2 inhibitors in patients undergoing elective coronary angiography (CAG) remains unclear. The aim of this study was to evaluate the effects of continuing versus withholding SGLT2 inhibitors on the incidence of contrast-associated AKI (CA-AKI) in patients undergoing elective CAG.
Methods
In this prospective, multicenter, open-label, randomized controlled trial, patients who had been using SGLT2 inhibitors for at least 3 months were randomly assigned to either continue ( n =102) or withhold ( n =98) their SGLT2 inhibitors during the periprocedural period. In the continuing group, patients maintained their SGLT2 inhibitor regimen uninterrupted, whereas in the withholding group, patients discontinued SGLT2 inhibitors 72 hours before CAG and resumed them after the procedure. The primary outcome was the incidence of CA-AKI, defined according to the Kidney Disease Improving Global Outcomes criteria. Secondary outcomes included changes in renal function, adverse events during hospitalization, and 90-day clinical outcomes.
Results
The incidence of CA-AKI was comparable between the two groups, occurring in 3.92% (4/102) of patients in the continuing group and 3.06% (3/98) in the withholding group (risk difference, 0.86%; 95% confidence interval, −4.22% to 5.94%; P = 0.74). The change in serum creatinine 48 hours after CAG was significantly lower in the continuing group (−0.06±0.15 mg/dl) than in the withholding group (−0.02±0.16 mg/dl), with a mean difference of −0.05 mg/dl (95% confidence interval, −0.09 to −0.004; P = 0.047). One patient in the continuing group developed diabetic ketoacidosis, and no other significant safety concerns were observed.
Conclusions
Among low-risk patients undergoing CAG, CA-AKI was rare, and withholding or continuing SGLT2 inhibitors had no meaningful effect on AKI risk or renal function. Routine discontinuation in this setting may not be necessary. Clinical Trial registry name and registration number: TCTR20230703004.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiovascular and Intervention Department, Central Chest Institute of Thailand, Nonthaburi, Thailand.
- Department of Radiology, Faculty of Medicine, Thammasat University Hospital, Pathum Thani, Thailand.
- Division of Nephrology, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathum Thani, Thailand.
- Cardiovascular and Intervention Department, Faculty of Medicine, Thammasat University Hospital, Pathum Thani, Thailand.
- Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
ORCID-Profile: Massupa Krisem, Thamarath Chantadansuwan, Pisit Hutayanon, Nattachai Srisawat, Peerapat Thanapongsatorn
Förderung
- Thammasat University
Zitieren
APA
Phatikraisri, T., Krisem, M., Chantadansuwan, T., Tantiyavarong, P., Hutayanon, P., Srisawat, N., & Thanapongsatorn, P. (2025). Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography. Kidney360, 6(8), 1317-1327. https://doi.org/10.34067/kid.0000000781
Vancouver
Phatikraisri T, Krisem M, Chantadansuwan T, Tantiyavarong P, Hutayanon P, Srisawat N, et al. Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography. Kidney360. 2025;6(8):1317-1327. doi:10.34067/kid.0000000781
BibTeX
@article{Phatikraisri2025,
author = {Phatikraisri, Theera and Krisem, Massupa and Chantadansuwan, Thamarath and Tantiyavarong, Pichaya and Hutayanon, Pisit and Srisawat, Nattachai and Thanapongsatorn, Peerapat},
title = {Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography},
journal = {Kidney360},
year = {2025},
volume = {6},
number = {8},
pages = {1317--1327},
doi = {10.34067/kid.0000000781}
}
EUVIMED